Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2013-12-09

Clinical Trial Update: Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 results from a study of carfilzomib in relapsed and refractory multiple myeloma have been posted. The trial (NCT00511238) is completed with results post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Carfilzomib (carfilzomib)

Snippet

Sponsor: Amgen | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2013-12-09